AZN Share Price

Open 34.11 Change Price %
High 34.51 1 Day 0.73 2.16
Low 33.76 1 Week 0.00 0.00
Close 34.50 1 Month -0.11 -0.32
Volume 5030951 1 Year 6.52 23.30
52 Week High 35.60
52 Week Low 25.55
AZN Important Levels
Resistance 2 35.20
Resistance 1 34.91
Pivot 34.26
Support 1 34.09
Support 2 33.80
NYSE USA Most Active Stocks
RAI 65.40 -2.23%
RAI 65.40 -2.23%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
GE 20.16 -1.22%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
TREX 109.45 25.65%
HZO 18.55 22.04%
SSD 55.74 14.62%
TBI 27.10 14.11%
SSTK 38.99 13.84%
KAI 113.60 13.09%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Astrazeneca PLC (NYSE: AZN)

AZN Technical Analysis 5
As on 31st Oct 2017 AZN Share Price closed @ 34.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 31.01 & Strong Buy for SHORT-TERM with Stoploss of 32.50 we also expect STOCK to react on Following IMPORTANT LEVELS.
AZN Target for November
1st Target up-side 35.37
2nd Target up-side 35.97
3rd Target up-side 36.58
1st Target down-side 33.63
2nd Target down-side 33.03
3rd Target down-side 32.42
AZN Other Details
Segment EQ
Market Capital 58447040512.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.astrazeneca.com
AZN Address
AZN
2 Kingdom Street
London, W2 6BD
United Kingdom
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151
AZN Latest News
Interactive Technical Analysis Chart Astrazeneca PLC ( AZN NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Astrazeneca PLC
AZN Business Profile
AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. and FibroGen, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.